GlaxoSmithKline, the manufacturer of Zofran, is seeking the dismissal of state failure-to-warn claims included in more than 200 birth defects lawsuits now consolidated in the U.S. District Court, District of Massachusetts. However, plaintiffs argue that such a move would be … Continue reading
A U.S. Congressman from Pennsylvania is calling for a criminal investigation into what he says are several uterine cancer deaths related to power morcellators. In a December 18th letter to the U.S. Food & Drug Administration’s (FDA) Office of Criminal … Continue reading
The multidistrict litigation established in the U.S. District Court, District of Massachusetts, for lawsuits involving Zofran and its alleged link to major birth defects, has begun to move forward. The proceeding’s first Status Conference was convened on December 16th, after … Continue reading
Levaquin lawsuit plaintiffs and others who allegedly developed peripheral neuropathy due to their use of fluoroquinolone antibiotics have asked a Pennsylvania judge to centralize their claims in the Philadelphia Court of Common Pleas. In a petition filed last month, the … Continue reading
A young man who was prescribed Risperdal as a child has been awarded $500,000 by a Pennsylvania jury, after the panel determined the drug’s manufacturers hadn’t properly warned patients and doctors about its potential to cause gynecomastia. The case was … Continue reading
Federally-filed Bair Hugger lawsuits will undergo coordinated pre-trial proceedings in the U.S. District Court, District of Minnesota, following an Order handed down Friday by the U.S. Judicial Panel on Multidistrict Litigation (JPML). The Panel’s December 11th Order initially transfers 14 … Continue reading
A Zofran lawsuit recently filed by Alabama parents seeks compensation for damage related to their son’s atrial septal defect. According to court documents, the complaint pending in the U.S. District Court, District of Alabama, claims that the child sustained the … Continue reading
The manufacturers of Invokana and other SGLT2 inhibitors have been ordered to add new safety warnings to their product labels, amid concerns that the Type 2 diabetes medications might cause ketoacidosis and serious urinary tract infections. The FDA also wants … Continue reading